Posted 10/17/2023, 10:21:48 AM
Johnson & Johnson Beats Earnings Estimates, Revenue Up on Pharma Strength; Investors Highlight Dividend Appeal
- Johnson & Johnson Non-GAAP EPS of $2.66 beats by $0.14, revenue of $21.35B beats by $300M
- Comments that JNJ is best of breed, dividend king, great for DGI
- Question about missing GLP-1 drugs and effects on cardiovascular & joint replacement businesses
- Noting growth is better than some overvalued stocks, low PE ratio and good dividend yield
- Long-term holders and buyers commenting it's a good buy at current levels
